SAN FRANCISCO, CA — The gene-editing technology CRISPR shows early promise as a therapeutic strategy for the aggressive and difficult-to-treat brain cancer known as primary glioblastoma, according to findings of a new study from Gladstone Institutes. Using a novel technique they’ve dubbed “cancer shredding,” the researchers programmed CRISPR to zero-in...
Latest News
SAN DIEGO – Cardea Bio, a Tech+Bio company integrating molecular biology with semiconductors electronics via graphene-based biology-gated Cardean Transistors, announced today that its Chief Science Officer, Dr. Kiana Aran, and collaborators published a paper entitled “Discrimination of single-point mutations in unamplified genomic DNA via Cas9 immobilized on a graphene field-effect...
TUCSON, Ariz. — Critical Path Institute (C-Path) is excited to announce the launch of the Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) Consortium. The CPA-1 consortium aims to accelerate drug development for alpha-1 antitrypsin deficiency (AATD), a rare disease that affects individuals and families worldwide. This will be achieved by...
CAMBRIDGE, Mass. — Crossbow Therapeutics, Inc., a biotechnology company focused on advancing T-Bolt™ therapies, a novel class of antibody therapeutics that mimic T-cell receptors (TCR-mimetics), today announced the nomination of its first development candidate, CBX-250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid leukemia. Researchers from...
MARBURG, Germany — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for...
King of Prussia, Pennsylvania – CSL Behring has released promising 3-year results from the pivotal HOPE-B study, confirming the sustained long-term durability and safety of etranacogene dezaparvovec-drlb (Hemgenix®) in individuals with hemophilia B. The data, demonstrating prolonged elevated factor IX activity levels following a single infusion, were recently presented at...
KING OF PRUSSIA, Pa. — CSL Behring, a business unit of global biotechnology leader CSL, today announced the availability of 4- and 5-gram vial sizes for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)]. Previously available only in a 1-gram vial, the 4- and 5-gram packaging is significant for the Alpha-1 community as it...
HATTERSHEIM AM MAIN, Germany – At this year’s fully virtual International Congress of the European Respiratory Society (ERS 2021), CSL Behring will be hosting a highly significant and topical virtual symposium on 6 September 2021, from 20:00 – 21:30 CEST. Focusing on what we have learnt about the impact of global Covid-19 pandemic...
ST. GALLEN, Switzerland — CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of sparsentan for the treatment of adults with primary IgAN with a urine protein excretion >1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). IgAN is a...
ST. GALLEN, Switzerland and SAN DIEGO, Calif. — CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio...